Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

Cognition Therapeutics Discusses Registrational Path for Zervimesine in DLB Psychosis with FDA

Cognition Therapeutics, Inc. held a productive meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026. The discussion focused on reviewing results from the Phase 2 COG1201 'SHIMMER' Study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) patients and outlining the design and endpoints for a registrational study in DLB patients with psychosis. The company expressed confidence in having established a clear path forward for the development of zervimesine for this indication, anticipating the FDA's formal minutes in June.

• Cognition Therapeutics engaged in a positive discussion with the FDA regarding the advancement of zervimesine into a registrational program for dementia with Lewy bodies (DLB) psychosis. The meeting successfully reviewed the strong efficacy signals observed in the Phase 2 COG1201 'SHIMMER' Study, paving the way for the design of a late-stage clinical trial.
• Zervimesine (CT1812) is highlighted as an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials for both DLB and mild-to-moderate Alzheimer’s disease. The drug has been generally well tolerated in studies to date, supporting its potential for further development in neurodegenerative disorders.
• The company's scientific approach is rooted in pioneering research into the underlying mechanisms of degenerative nerve disorders, specifically targeting toxic oligomers that drive disease progression. This strategy offers broad therapeutic potential across various indications, including DLB, Alzheimer’s disease, geographic atrophy, and Parkinson’s.

Addressing the Unmet Needs in DLB Psychosis

Current treatment approaches for DLB psychosis face significant therapeutic challenges, primarily due to patients' heightened sensitivity to conventional antipsychotic medications. The distinct pathophysiologic features of DLB create a complex treatment landscape where standard psychosis management strategies often prove inadequate or harmful.

• Antipsychotic hypersensitivity: DLB patients demonstrate exceptional sensitivity to antipsychotic agents, with adverse effects including somnolence, sedation, extrapyramidal symptoms, delirium, and increased mortality risk, particularly in elderly populations

• Motor symptom deterioration: Antidopaminergic medications consistently worsen motor and neuropsychiatric symptoms, including cognition and psychosis, creating a therapeutic paradox where treating psychosis may exacerbate underlying parkinsonism

• Limited medication options: Traditional first-generation antipsychotics (haloperidol) and second-generation agents (olanzapine, risperidone, quetiapine) frequently cause severe side effects without meaningful psychosis improvement, severely restricting treatment choices

• Cardiovascular and mortality risks: Atypical antipsychotics, particularly olanzapine and risperidone, increase stroke risk threefold in dementia patients, while overall mortality risk remains elevated across antipsychotic classes

• Dosing complexities: Even low-dose antipsychotic regimens can cause problematic effects, such as quetiapine at 50mg causing excessive sedation and confusion, requiring careful titration and monitoring

• Drug interaction concerns: Combination therapies, including antipsychotics with cholinesterase inhibitors like donepezil, may precipitate malignant syndrome and worsen extrapyramidal symptoms, particularly in nutritionally compromised patients

• Inadequate care delivery: Clinical practice reveals suboptimal treatment patterns, with high antipsychotic usage (25-43%) and insufficient anti-dementia medication utilization in nursing home populations with DLB features

• End-of-life complications: Behavioral symptoms, particularly delusions, significantly impact caregiver experiences during terminal care phases, requiring specialized management strategies throughout the disease course

Zervimesine's Phase 2 SHIMMER Study Outcomes in DLB

Recent clinical investigations in dementia with Lewy bodies (DLB) with psychosis have explored several therapeutic approaches with varying degrees of success. A phase 2 randomized, double-blind study of nilotinib (200 mg daily for 6 months) in 43 participants demonstrated promising safety and efficacy outcomes. The study showed that nilotinib was well-tolerated with fewer adverse events compared to placebo (37 vs 74 events, p = 0.054) and significantly reduced falls (6 vs 21, p = 0.006). Cognitive improvements were observed on the Alzheimer's Disease Assessment Scale-cognition 14 (2.8-point improvement, p = 0.037) and MDS-UPDRS part I cognition scores (p = 0.044), while cerebrospinal fluid biomarkers showed increased homovanillic acid levels (p = 0.004) and reduced pTau181/Aβ42 ratios (p = 0.034).

A complementary study investigated vodobatinib (K0706) in a three-arm trial with 29 participants receiving either 192 mg, 384 mg, or placebo for 3 months. Vodobatinib demonstrated excellent safety profiles with markedly fewer adverse events in both treatment arms compared to placebo (19 and 6 events respectively vs 56 for placebo). Falls were substantially reduced in the 192 mg group (6 falls) and completely eliminated in the 384 mg group compared to placebo (28 falls). However, exploratory clinical outcomes showed no significant differences from baseline, suggesting that longer treatment periods may be necessary to demonstrate clinical efficacy despite the favorable safety profile.

Non-pharmacological approaches have also shown efficacy, particularly electroconvulsive therapy (ECT) for severe neuropsychiatric symptoms. A retrospective analysis of 40 LBD patients who received ECT between 2012-2023 revealed comparable short-term efficacy to schizophrenia patients (median Clinical Global Impressions-Improvement scale of 2), with psychosis and catatonia serving as predictors of favorable response. ECT was well-tolerated with no serious adverse events, though transient amnesia was commonly reported. Additionally, diagnostic advances using skin biopsy to detect phosphorylated alpha-synuclein in cutaneous nerves showed promise, with two of four psychotic patients testing positive for synucleinopathy, highlighting the importance of accurate diagnosis given DLB patients' extreme sensitivity to antipsychotic medications.

Shaping the Registrational Program for Zervimesine in DLB

Clinical trials in dementia with Lewy bodies (DLB) with psychosis employ diverse endpoint measures, though standardization remains a significant challenge. Current studies utilize both established neuropsychiatric assessment tools and novel DLB-specific measures to capture the complex symptom profile of this condition.

• Neuropsychiatric Inventory (NPI) serves as a primary endpoint measure for assessing behavioral and psychological symptoms in DLB patients, including psychotic manifestations such as hallucinations and delusions

• Lewy body Neuropsychiatric Supportive Symptom Count (LBNSSC) represents a specialized endpoint based on 2017 DLB diagnostic criteria, evaluating non-visual hallucinations, delusions, anxiety, depression, and apathy, with DLB patients demonstrating significantly higher scores than Alzheimer's disease patients (1.8 ± 1.1 vs. 0.7 ± 0.9)

• Reduction in frequency and severity of hallucinations and delusions constitutes a core primary endpoint in pimavanserin trials, alongside assessment of relapse risk for these psychotic symptoms in dementia-related psychosis

• Dementia Cognitive Fluctuations Scale is employed to capture the characteristic cognitive fluctuations that distinguish DLB from other dementias, representing a unique endpoint specific to this condition

• Mini-Mental State Examination (MMSE) tracking over extended periods (up to 60 months) serves as a longitudinal endpoint to monitor cognitive decline progression in DLB versus other dementia types

• Factor analysis of psychotic symptoms provides a sophisticated approach to endpoint measurement, allowing for detailed characterization of the psychotic symptom profile in clinically diagnosed DLB patients

The Evolving Treatment Landscape for Dementia with Lewy Bodies

The treatment landscape for dementia with Lewy bodies (DLB) psychosis has undergone significant evolution over the past five years, with emerging evidence supporting targeted therapeutic approaches and refined safety protocols. Recent clinical data reveals a concerning pattern where antipsychotics are frequently prescribed as first-line treatment despite established guidelines recommending acetylcholinesterase inhibitors (AChEIs). A 2025 study of 362 individuals with LBD symptoms found that 31.5% received antipsychotics as initial therapy, with first-line AChEI treatment being more common among males and nursing home residents. This practice diverges from current recommendations positioning AChEIs as safer first-line options for managing cognitive and neuropsychiatric symptoms in DLB.

Pimavanserin has emerged as the most promising therapeutic advancement for DLB psychosis management during this period. Multiple case series and reports from 2023-2024 demonstrate consistent efficacy and tolerability profiles, with a notable 2024 case series showing that three of four male DLB patients experienced significant reduction in hallucinations, delusions, and paranoia when treated with pimavanserin. This serotonin 5HT-2A receptor inverse agonist, originally FDA-approved for Parkinson's disease psychosis, offers particular advantages as it improves psychotic symptoms without exacerbating motor dysfunction. Additional evidence supports combination therapy approaches, with pimavanserin plus trazodone showing marked improvement in three DLB patients, reducing Neuropsychiatric Inventory scores from a mean of 88 to 38 after 4-6 weeks of treatment.

The evolving safety landscape reflects increased awareness of antipsychotic-related risks in DLB populations, with mounting evidence of motor and cognitive deterioration associated with traditional antipsychotics. Recent case reports document significant clinical worsening with olanzapine, haloperidol, risperidone, and quetiapine, often without meaningful psychosis improvement. This has prompted implementation of Best Practice Alerts in electronic health record systems to identify patients prone to neuroleptic sensitivity. Concurrently, electroconvulsive therapy has gained recognition as a viable non-pharmacological option, with 2024 data showing 80% of DLB patients achieved much or very much improvement in psychiatric symptoms while also demonstrating unexpected benefits for parkinsonism and cognitive function.

Pivotal Step for Zervimesine in DLB Psychosis

The recent productive FDA meeting for zervimesine (CT1812) in dementia with Lewy bodies (DLB) patients, particularly those experiencing psychosis, signals a pivotal moment for Cognition Therapeutics and the broader neurodegeneration landscape. Zervimesine, a first-in-class sigma-2 receptor (S2R) modulator, has demonstrated a unique mechanism of action by preventing and displacing amyloid beta (Aβ) oligomers from neuronal synapses, thereby mitigating synaptotoxicity. This synaptoprotective effect, supported by extensive preclinical and Phase 2 clinical data in Alzheimer's disease (AD) patients, including replicated biomarker findings and improvements in qEEG markers of synaptic function, positions zervimesine as a potential disease-modifying therapy.

For DLB, a condition characterized by significant cognitive and non-motor symptoms like psychosis, the establishment of a clear path forward for a registrational study is a critical development. Current therapeutic options for psychosis in DLB are limited and often associated with safety concerns, leaving a substantial unmet need. Zervimesine's potential to address both the underlying pathology and a debilitating symptom like psychosis could offer a significant advantage.

However, several considerations warrant attention as development progresses:

• While the S2R modulation mechanism is compelling, the specific efficacy and safety data from the Phase 2 'SHIMMER' study in DLB with psychosis, distinct from the AD trials, will be crucial for validating its clinical benefit in this specific population.

• The safety profile, generally well-tolerated in AD and healthy cohorts with mild GI and headache AEs, must be rigorously evaluated in the more vulnerable DLB patient group, especially those with psychosis, where polypharmacy and comorbidities are common.

• The extensive biomarker and qEEG evidence, largely derived from AD studies, will need to be robustly correlated with clinical outcomes in DLB to confirm their predictive value and relevance in this distinct disease context.

This regulatory alignment suggests an accelerated pathway, potentially allowing zervimesine to emerge as a novel, disease-modifying option for a challenging indication. Its success could not only transform DLB treatment but also further validate S2R modulation as a broader strategy for neurodegenerative disorders.